Robert Huebner, PhD
Dr. Huebner is an experienced biotechnology program manager with over thirty years of research experience with viral and microbiological pathogens and expertise in the vaccine industry, group management, and program management. Throughout his career, he has worked for a variety of organizations, large pharma companies, government agencies, and a contract research organization, holding positions of increasing responsibility at each. At the Latham BioPharm Group (LBG), he supports both commercial and US Government funded programs as a subject matter expert on biopharmaceutical development, analytics and program management. He also leads efforts to help clients win and secure non-dilutive US Government funding. Prior to joining LBG, Dr. Huebner worked at the Biomedical Research and Development Authority (BARDA) of the Department of Health and Human Services where he held several positions including Acting Director of the Influenza Division, Deputy Director and Chief of Universal Influenza Vaccine Development. While serving as Acting Director, he was responsible for over 50 programs valued in excess of $5 billion. His tenure in this position was highlighted by the licensure of three new types of influenza vaccines, and approval of a new near patient diagnostic platform for influenza and RSV. Prior to BARDA, working at MRIGlobal, Dr. Huebner grew the client base for the biotechnology section he managed, bringing in projects from US Government and industrial clients to work on vaccines, detection methods and destruction methods for bacterial and viral pathogen. Dr. Huebner started his career as a bench scientist and group leader at Sanofi Pasteur working on applied research to develop new and improved vaccines against Lyme disease, influenza, Dengue, Japanese Encephalitis, malaria and pneumococcal disease. Dr. Huebner received a Ph.D. in Molecular Biology and Microbiology from Tufts University in Boston, MA and a B.S. in Biology from Carnegie Mellon University, Pittsburgh, PA.